Brief: Inhibikase Therapeutics To Present Data From Phase 1/1B Study Of IkT-148009 At The Movement Disorders Society Congress

Inhibikase Therapeutics

15/09/2022 13:37

Sept 15 (Reuters) - Inhibikase Therapeutics Inc  IKT.O :
    * INHIBIKASE THERAPEUTICS TO PRESENT DATA FROM PHASE 1/1B
STUDY OF
IKT-148009 AT THE MOVEMENT DISORDERS SOCIETY CONGRESS
    * INHIBIKASE THERAPEUTICS INC - NO CLINICALLY SIGNIFICANT
ADVERSE
EVENTS OBSERVED
    * INHIBIKASE THERAPEUTICS INC - ACTIVELY ENROLLING PHASE 2A
'201'
CLINICAL TRIAL OF IKT-148009 IN PATIENTS WITH UNTREATED
PARKINSON'S DISEASE
    * INHIBIKASE - IKT-148009 WAS WELL-TOLERATED WITH HIGH
SYSTEMIC
EXPOSURE, PERSISTENT PENETRATION INTO CNS IN OLDER, ELDERLY
HEALTHY VOLUNTEERS, PARKINSON'S PATIENTS

Source text for Eikon:  ID:nPn1vtc9qa 
Further company coverage:  IKT.O 

 ((Reuters.Briefs@thomsonreuters.com;))